<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Rocha BA</submitter><funding>Fundação de Amparo à Pesquisa do Estado de São Paulo</funding><pagination>152102</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4058456</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2014</volume><pubmed_abstract>Monensin A is a commercially important natural product isolated from Streptomyces cinnamonensins that is primarily employed to treat coccidiosis. Monensin A selectively complexes and transports sodium cations across lipid membranes and displays a variety of biological properties. In this study, we evaluated the Jacobsen catalyst as a cytochrome P450 biomimetic model to investigate the oxidation of monensin A. Mass spectrometry analysis of the products from these model systems revealed the formation of two products: 3-O-demethyl monensin A and 12-hydroxy monensin A, which are the same ones found in in vivo models. Monensin A and products obtained in biomimetic model were tested in a mitochondrial toxicity model assessment and an antimicrobial bioassay against Staphylococcus aureus, S. aureus methicillin-resistant, Staphylococcus epidermidis, Pseudomonas aeruginosa, and Escherichia coli. Our results demonstrated the toxicological effects of monensin A in isolated rat liver mitochondria but not its products, showing that the metabolism of monensin A is a detoxification metabolism. In addition, the antimicrobial bioassay showed that monensin A and its products possessed activity against Gram-positive microorganisms but not for Gram-negative microorganisms. The results revealed the potential of application of this biomimetic chemical model in the synthesis of drug metabolites, providing metabolites for biological tests and other purposes.</pubmed_abstract><journal>BioMed research international</journal><pubmed_title>Jacobsen catalyst as a cytochrome P450 biomimetic model for the metabolism of monensin A.</pubmed_title><pmcid>PMC4058456</pmcid><funding_grant_id>2013/17658-9</funding_grant_id><funding_grant_id>2011/05800-0</funding_grant_id><pubmed_authors>de Moraes LA</pubmed_authors><pubmed_authors>Berretta AA</pubmed_authors><pubmed_authors>Gates PJ</pubmed_authors><pubmed_authors>Rodrigues AP</pubmed_authors><pubmed_authors>Lopes NP</pubmed_authors><pubmed_authors>Rocha BA</pubmed_authors><pubmed_authors>Dorta DJ</pubmed_authors><pubmed_authors>Pazin M</pubmed_authors><pubmed_authors>Peti AP</pubmed_authors><pubmed_authors>de Oliveira AR</pubmed_authors><pubmed_authors>Assis Md</pubmed_authors><pubmed_authors>Pospisil S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Jacobsen catalyst as a cytochrome P450 biomimetic model for the metabolism of monensin A.</name><description>Monensin A is a commercially important natural product isolated from Streptomyces cinnamonensins that is primarily employed to treat coccidiosis. Monensin A selectively complexes and transports sodium cations across lipid membranes and displays a variety of biological properties. In this study, we evaluated the Jacobsen catalyst as a cytochrome P450 biomimetic model to investigate the oxidation of monensin A. Mass spectrometry analysis of the products from these model systems revealed the formation of two products: 3-O-demethyl monensin A and 12-hydroxy monensin A, which are the same ones found in in vivo models. Monensin A and products obtained in biomimetic model were tested in a mitochondrial toxicity model assessment and an antimicrobial bioassay against Staphylococcus aureus, S. aureus methicillin-resistant, Staphylococcus epidermidis, Pseudomonas aeruginosa, and Escherichia coli. Our results demonstrated the toxicological effects of monensin A in isolated rat liver mitochondria but not its products, showing that the metabolism of monensin A is a detoxification metabolism. In addition, the antimicrobial bioassay showed that monensin A and its products possessed activity against Gram-positive microorganisms but not for Gram-negative microorganisms. The results revealed the potential of application of this biomimetic chemical model in the synthesis of drug metabolites, providing metabolites for biological tests and other purposes.</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014</publication><modification>2024-12-03T19:22:02.538Z</modification><creation>2019-03-27T01:30:14Z</creation></dates><accession>S-EPMC4058456</accession><cross_references><pubmed>24987668</pubmed><doi>10.1155/2014/152102</doi></cross_references></HashMap>